Get the Stockscreener App
4.35
0.69%
0.03
Eledon Pharmaceuticals Inc stock is traded at $4.35, with a volume of 766.89K.
It is up +0.69% in the last 24 hours and up +53.17% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$4.32
Open:
$4.37
24h Volume:
766.89K
Relative Volume:
0.66
Market Cap:
$260.49M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-2.4302
EPS:
-1.79
Net Cash Flow:
$-39.53M
1W Performance:
+13.58%
1M Performance:
+53.17%
6M Performance:
+31.42%
1Y Performance:
-17.92%
1-Day Range:
$4.13
$4.60
1-Week Range:
$3.67
$4.60
52-Week Range:
$2.315
$5.44
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
4.35 | 258.69M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Published on: 2025-11-03 08:17:43 - newser.com
Market reaction to Eledon Pharmaceuticals Inc.’s recent news2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock attractive post correctionSwing Trade & Risk Managed Investment Strategies - newser.com
Using AI based signals to follow Eledon Pharmaceuticals Inc.Weekly Investment Report & Verified Short-Term Trading Plans - newser.com
Will Eledon Pharmaceuticals Inc. (2TK) stock beat revenue estimates2025 Trade Ideas & Free AI Powered Buy and Sell Recommendations - newser.com
Real time scanner hits for Eledon Pharmaceuticals Inc. explainedJuly 2025 Macro Moves & Daily Growth Stock Tips - newser.com
Visual trend scoring systems applied to Eledon Pharmaceuticals Inc.Weekly Trade Recap & Entry Point Confirmation Alerts - newser.com
Can Eledon Pharmaceuticals Inc. recover in the next quarterProfit Target & Verified Stock Trade Ideas - newser.com
Eledon Pharmaceuticals Inc. stock momentum explainedJuly 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com
Why Eledon Pharmaceuticals Inc. (2TK) stock stays on buy listsTrade Volume Report & Short-Term High Return Ideas - newser.com
Why Eledon Pharmaceuticals Inc. (2TK) stock could be top winnerDay Trade & Capital Protection Trade Alerts - newser.com
Will Eledon Pharmaceuticals Inc. stock gain from lower inflationEarnings Risk Summary & Weekly Top Gainers Alerts - newser.com
Why analysts remain bullish on Eledon Pharmaceuticals Inc. stockCPI Data & Daily Profit Maximizing Tips - newser.com
Can Eledon Pharmaceuticals Inc. (2TK) stock double in coming yearsGap Down & Long-Term Investment Growth Plans - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock supported by strong fundamentalsBull Run & Target Return Focused Stock Picks - newser.com
What dividend safety rating applies to Eledon Pharmaceuticals Inc. (2TK) stockMarket Volume Summary & Community Consensus Stock Picks - newser.com
Will breakout in Eledon Pharmaceuticals Inc. lead to full recoveryJuly 2025 Rallies & Real-Time Volume Spike Alerts - newser.com
Is Eledon Pharmaceuticals Inc. stock a buy in volatile marketsJuly 2025 Short Interest & High Conviction Trade Alerts - newser.com
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Declines By 47.4% - MarketBeat
How Eledon Pharmaceuticals Inc. (2TK) stock valuation compares with sectorJuly 2025 Price Swings & Verified Trade Idea Suggestions - newser.com
Published on: 2025-11-01 03:53:10 - newser.com
Published on: 2025-10-31 05:05:04 - newser.com
Is this a good reentry point in Eledon Pharmaceuticals Inc.2025 Dividend Review & Free Accurate Trade Setup Notifications - newser.com
Eledon Pharmaceuticals’ AT 1501: A Promising Kidney Transplant Study Update - TipRanks
Published on: 2025-10-31 03:44:59 - newser.com
Eledon Pharmaceuticals Inc. stock daily chart insights2025 Valuation Update & Reliable Momentum Entry Alerts - newser.com
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):